Tetsuro Hikichi - Search Results

Year	Number of Results
2002	1
2014	1
2018	1
2019	1
2020	5
2021	2
2022	2

1

Clinical Trial of a Cancer Vaccine Targeting VEGF and KIF20A in Advanced Biliary Tract Cancer.

Murahashi M, Tsuruta T, Yamada K, Hijikata Y, Ogata H, Kishimoto J, Yoshimura S, Hikichi T, Nakanishi Y, Tani K. Murahashi M, et al. Among authors: hikichi t. Anticancer Res. 2021 Mar;41(3):1485-1496. doi: 10.21873/anticanres.14907. Anticancer Res. 2021. PMID: 33788741 Clinical Trial.

2

Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2.

Tamura R, Fujioka M, Morimoto Y, Ohara K, Kosugi K, Oishi Y, Sato M, Ueda R, Fujiwara H, Hikichi T, Noji S, Oishi N, Ogawa K, Kawakami Y, Ohira T, Yoshida K, Toda M. Tamura R, et al. Among authors: hikichi t. Nat Commun. 2020 Apr 21;11(1):2028. doi: 10.1038/s41467-020-16007-z. Nat Commun. 2020. PMID: 32317644 Free PMC article.

3

A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2.

Tamura R, Fujioka M, Morimoto Y, Ohara K, Kosugi K, Oishi Y, Sato M, Ueda R, Fujiwara H, Hikichi T, Noji S, Oishi N, Ogawa K, Kawakami Y, Ohira T, Yoshida K, Toda M. Tamura R, et al. Among authors: hikichi t. Nat Commun. 2019 Dec 17;10(1):5758. doi: 10.1038/s41467-019-13640-1. Nat Commun. 2019. PMID: 31848332 Free PMC article. Clinical Trial.

4

Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.

Morisaki T, Hikichi T, Onishi H, Morisaki T, Kubo M, Hirano T, Yoshimura S, Kiyotani K, Nakamura Y. Morisaki T, et al. Among authors: hikichi t. Immunol Invest. 2021 Jul;50(5):562-579. doi: 10.1080/08820139.2020.1778721. Epub 2020 Jul 13. Immunol Invest. 2021. PMID: 32660279

5

Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.

Tamura R, Morimoto Y, Kosugi K, Sato M, Oishi Y, Ueda R, Kikuchi R, Nagashima H, Hikichi T, Noji S, Kawakami Y, Sasaki H, Yoshida K, Toda M. Tamura R, et al. Among authors: hikichi t. BMC Cancer. 2020 Mar 12;20(1):196. doi: 10.1186/s12885-020-6589-x. BMC Cancer. 2020. PMID: 32164575 Free PMC article. Clinical Trial.

6

Correction to: Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.

Tamura R, Morimoto Y, Kosugi K, Sato M, Oishi Y, Ueda R, Kikuchi R, Nagashima H, Hikichi T, Noji S, Kawakami Y, Sasaki H, Yoshida K, Toda M. Tamura R, et al. Among authors: hikichi t. BMC Cancer. 2020 Apr 14;20(1):301. doi: 10.1186/s12885-020-06783-8. BMC Cancer. 2020. PMID: 32290821 Free PMC article.

7

A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma.

Tamura R, Morimoto Y, Sato M, Hikichi T, Yoshida K, Toda M. Tamura R, et al. Among authors: hikichi t. Vaccines (Basel). 2020 Sep 2;8(3):498. doi: 10.3390/vaccines8030498. Vaccines (Basel). 2020. PMID: 32887369 Free PMC article.

8

Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells.

Kato T, Matsuda T, Ikeda Y, Park JH, Leisegang M, Yoshimura S, Hikichi T, Harada M, Zewde M, Sato S, Hasegawa K, Kiyotani K, Nakamura Y. Kato T, et al. Among authors: hikichi t. Oncotarget. 2018 Jan 13;9(13):11009-11019. doi: 10.18632/oncotarget.24232. eCollection 2018 Feb 16. Oncotarget. 2018. PMID: 29541393 Free PMC article.

9

Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2).

Yoshimura S, Tsunoda T, Osawa R, Harada M, Watanabe T, Hikichi T, Katsuda M, Miyazawa M, Tani M, Iwahashi M, Takeda K, Katagiri T, Nakamura Y, Yamaue H. Yoshimura S, et al. Among authors: hikichi t. PLoS One. 2014 Jan 8;9(1):e85267. doi: 10.1371/journal.pone.0085267. eCollection 2014. PLoS One. 2014. PMID: 24416375 Free PMC article.

10

Identification of cytotoxic T cells and their T cell receptor sequences targeting COVID-19 using MHC class I-binding peptides.

Hikichi T, Sakamoto M, Harada M, Saito M, Yamane Y, Tokumura K, Nakamura Y. Hikichi T, et al. J Hum Genet. 2022 Jul;67(7):411-419. doi: 10.1038/s10038-022-01013-4. Epub 2022 Feb 2. J Hum Genet. 2022. PMID: 35110673 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results